deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT02577926

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT)

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

Sponsor: Novartis Pharmaceuticals

Conditions Essential Thrombocythemia (ET) Polycythemia Vera (PV)
Interventions BAT Ruxolitinib
Updated 19 times since 2017 Last updated: Jun 5, 2025 Started: Oct 31, 2015 Primary completion: Dec 31, 2027 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02577926, this PHASE2 trial focuses on Essential Thrombocythemia (ET) and Polycythemia Vera (PV) and remains ongoing. Sponsored by Novartis Pharmaceuticals, it has been updated 19 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Jan 2018 · 7 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Dec 2019 · 17 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Nov 2022 · 22 months · monthly snapshot~Nov 2022 – ~Dec 2023 · 13 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  8. Apr 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  9. Dec 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  10. Jul 2018 — Dec 2019 [monthly]

    Recruiting PHASE2

  11. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  12. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Phase: PHASE3 → PHASE2

  13. Jun 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  14. Jan 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
  • RWTH Aachen University
Data source: RWTH Aachen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aschaffenburg, Germany , Berlin, Germany , Bonn, Germany , Chemnitz, Germany , Dresden, Germany , Duisburg, Germany , Düsseldorf, Germany , Essen, Germany , Freiburg im Breisgau, Germany and 12 more locations